BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35440669)

  • 1. Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.
    Umeh-Garcia M; O'Geen H; Simion C; Gephart MH; Segal DJ; Sweeney CA
    Br J Cancer; 2022 Aug; 127(3):436-448. PubMed ID: 35440669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer.
    Good CR; Panjarian S; Kelly AD; Madzo J; Patel B; Jelinek J; Issa JJ
    Cancer Res; 2018 Aug; 78(15):4126-4137. PubMed ID: 29891505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
    Bagu ET; Miah S; Dai C; Spriggs T; Ogunbolude Y; Beaton E; Sanders M; Goel RK; Bonham K; Lukong KE
    Oncotarget; 2017 Feb; 8(7):11442-11459. PubMed ID: 28077797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.
    Kai M; Niinuma T; Kitajima H; Yamamoto E; Harada T; Aoki H; Maruyama R; Toyota M; Sasaki Y; Sugai T; Tokino T; Nakase H; Suzuki H
    PLoS One; 2016; 11(12):e0168281. PubMed ID: 27977763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter.
    Choudhury SR; Cui Y; Lubecka K; Stefanska B; Irudayaraj J
    Oncotarget; 2016 Jul; 7(29):46545-46556. PubMed ID: 27356740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
    Mossman D; Kim KT; Scott RJ
    BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
    Pulukuri SM; Rao JS
    Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
    Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.
    Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y
    Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
    Barrio-Real L; Benedetti LG; Engel N; Tu Y; Cho S; Sukumar S; Kazanietz MG
    Breast Cancer Res; 2014 Sep; 16(5):441. PubMed ID: 25248717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.
    Augoff K; McCue B; Plow EF; Sossey-Alaoui K
    Mol Cancer; 2012 Jan; 11():5. PubMed ID: 22289355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
    Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
    Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Putative promoters within gene bodies control exon expression via TET1-mediated H3K36 methylation.
    Ma L; Muhammad T; Wang H; Du G; Sakhawat A; Wei Y; Ali Khan A; Cong X; Huang Y
    J Cell Physiol; 2020 Oct; 235(10):6711-6724. PubMed ID: 31994732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
    Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
    BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
    Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
    Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.